ADVFN - Advanced Financial Network.
HOME» NYSE » V » VRX Stock Price » VRX Stock News

Valeant Pharma Share News

 Valeant Pharmaceuticals International Stock Price
VRX Stock Price
 Valeant Pharmaceuticals International Stock Chart
VRX Stock Chart
 Valeant Pharmaceuticals International Stock News
VRX Stock News
 Valeant Pharmaceuticals International Company Information
VRX Company Information
 Valeant Pharmaceuticals International Stock Trades
VRX Stock Trades

Cephalon 2Q Profit Rises 33%, Adjusted Net Falls On Weak Sales

DOW JONES NEWSWIRES Cephalon Inc.'s (CEPH) second-quarter earnings rose 33% on an investment gain, but the biopharmaceutical company's adjusted profit fell, breaking a long streak, on weak sales for central nervous systems drugs. Sales of central-nervous-system drugs, the company's top-selling category, dropped 4.8%, while the smaller divisions for pain and oncology products saw sales rise 4.4% and 22%, respectively. The company's core profit had increased for three years straight until the latest period. The pace of growth in central-nervous-system drugs had been abating before declining in the latest period, as have the rates for pain and oncology. Cephalon posted a profit of $118.2 million, or $1.34 a share, from $89.1 million, or $1.11 a share, a year earlier. The latest results included a large gain on the fair value of investments, among other items. Excluding them, adjusted earnings fell to $1.62 a share from $2.05. Revenue increased 1.6% to $738.3 million. Analysts expected earnings of $2.06 a share on revenue of $764 million. Gross margin as a percentage of total revenue rose to 83.2% from 76.5%. But costs for research and development jumped 33%. In May, Cephalon agreed to a takeover by Teva Pharmaceutical Industries Ltd. (TEVA, TEVA.TV) for $6.8 billion, which prevailed over a hostile bid from Valeant Pharmaceuticals International Inc. (VRX, VRX.T). In June, U.S. antitrust regulators requested more details about the deal, a development Teva said it expected. Shares were up 0.2% at $80.09 after hours. Through the close, the stock has risen 30% so far this year, better than the wider market. -By Joan E. Solsman, Dow Jones Newswires; 212-416-2291;

Stock News for Valeant Pharma (VRX)
11/25/201511:30:00Prescription Skin Drugs Explode in Costs, Study Shows
11/24/201516:21:51Statement of Changes in Beneficial Ownership (4)
11/24/201509:48:00U.S. Hot Stocks: Hot Stocks to Watch
11/24/201503:02:00Ackman's Pershing Buys More Of Valeant
11/23/201518:20:00Ackman's Pershing Square Boosts Stake in Valeant to 9.9%
11/23/201517:14:20Amended Statement of Beneficial Ownership (sc 13d/a)
11/23/201507:50:00Pfizer and Allergan Strike Huge Inversion Deal
11/22/201520:40:00Pfizer, Allergan Agree to Merge
11/22/201520:37:00Concerns Over Valeant Spread to Other Drug Makers
11/21/201513:00:033 Stocks Wall Street Hates
11/20/201517:43:47EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class...
11/20/201512:44:03Bill Ackman's Pershing Square Hedge Fund Is Hanging On to This...
11/20/201510:30:00VRX Investor Deadline Alert: Law Offices of Howard G. Smith Reminds...
11/20/201510:26:00/C O R R E C T I O N -- Valeant Pharmaceuticals International...
11/20/201510:26:00/C O R R E C T I O N -- Valeant Pharmaceuticals International...
11/20/201508:41:03How 1 Specialty-Drug Maker Hopes to Win Back Investor Trust
11/20/201508:39:03Should You Own Lone Pine Capital's 3 Favorite Stocks?
11/20/201508:00:00Valeant To Hold Investor Day On December 16
11/20/201508:00:00Valeant To Hold Investor Day On December 16

Valeant Pharma and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations